The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
New drugs and perspectives for new anti-tuberculosis regimens ☆
Open accessAbstract
Tuberculosis (TB) is the ninth cause of global death, more than any other infectious disease. With growing drug resistance the epidemic remains and will require significant attention and investment for the elimination of this disease to occur. With susceptible TB treatment not changing over the last four decades and the advent of drug resistance, new drugs and regimens are required. Recently, through greater collaboration and research networks some progress with significant advances has taken place, not withstanding the comparatively low amount of resources invested. Of late the availability of the new drugs bedaquiline, delamanid and repurposed drugs linezolid, clofazimine and carbapenems are being used more frequently in drug-resistant TB regimens. The WHO shorter multidrug-resistant tuberculosis regimen promises to reach more patients and treat them more quickly and more cheaply. With this new enthusiasm and hope we this review gives an update on the new drugs and perspectives for the treatment of drug-susceptible and drug-resistant tuberculosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peloquin, C. A., Dorman, S. E., Vernon, A., Battista Migliori, G., & Nahid, P. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw679 · Cited by 6
Cited by
Recent updates on drug resistance in Mycobacterium tuberculosis
Singh, R., Dwivedi, S. P., Gaharwar, U. S., Meena, R., Rajamani, P., & Prasad, T. (2020) · Journal of Applied Microbiology · doi:10.1111/jam.14478 · Cited by 337
Karthikeyan, A., Joseph, A., & Nair, B. G. (2022) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-021-00290-4 · Cited by 336
Metadata
- Authors
- Tiberi, S., Muñoz-Torrico, M., Duarte, R., Dalcolmo, M., D’Ambrosio, L., & Migliori, G.-B.
- Venue
- Pulmonology
- Publisher
- Informa UK Limited
- Published
- 2018-03-30
- Volume
- 24
- Issue
- 2
- Pages
- 86-98
- ISSN
- 2531-0429 (ISSN-L)
- 2531-0437
- OpenAlex
- W2790605859
- Cited by
- 179
- References
- 1
- FWCI
- 15.73
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New drugs and perspectives for new anti-tuberculosis regimens ☆. https://app.cochat.ai/papers/10.1016/j.rppnen.2017.10.009
- The paper
- Tiberi, S., Muñoz-Torrico, M., Duarte, R., Dalcolmo, M., D’Ambrosio, L., & Migliori, G.-B. (2018). New drugs and perspectives for new anti-tuberculosis regimens ☆. Pulmonology. https://doi.org/10.1016/j.rppnen.2017.10.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.